[go: up one dir, main page]

WO2006087629A3 - Rapidly disintegrating composition of olanzapine - Google Patents

Rapidly disintegrating composition of olanzapine Download PDF

Info

Publication number
WO2006087629A3
WO2006087629A3 PCT/IB2006/000330 IB2006000330W WO2006087629A3 WO 2006087629 A3 WO2006087629 A3 WO 2006087629A3 IB 2006000330 W IB2006000330 W IB 2006000330W WO 2006087629 A3 WO2006087629 A3 WO 2006087629A3
Authority
WO
WIPO (PCT)
Prior art keywords
olanzapine
rapidly disintegrating
disintegrating composition
composition
rapidly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/000330
Other languages
French (fr)
Other versions
WO2006087629A2 (en
Inventor
Chandra Sekhara Redd Nagareddy
Ramesh Cheruvu
Kishor Dattatray Deo
Sivakumaran Meenakshisunderam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurobindo Pharma Ltd
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Publication of WO2006087629A2 publication Critical patent/WO2006087629A2/en
Publication of WO2006087629A3 publication Critical patent/WO2006087629A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to rapidly disintegrating dosage form of olanzapine with no binding agent comprising of about 1-10% olanzapine, about 1-10% of disintegrant, about 70-85% of filler, and about 0.4-7% of lubricant.
PCT/IB2006/000330 2005-02-21 2006-02-20 Rapidly disintegrating composition of olanzapine Ceased WO2006087629A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN143CH2005 2005-02-21
IN143/CHE/2005 2005-02-21

Publications (2)

Publication Number Publication Date
WO2006087629A2 WO2006087629A2 (en) 2006-08-24
WO2006087629A3 true WO2006087629A3 (en) 2006-11-02

Family

ID=36644929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/000330 Ceased WO2006087629A2 (en) 2005-02-21 2006-02-20 Rapidly disintegrating composition of olanzapine

Country Status (1)

Country Link
WO (1) WO2006087629A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200903293A1 (en) * 2009-04-28 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral disintegrating olanzapine tablet.
WO2012153347A2 (en) * 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
CN105377303B (en) * 2013-07-19 2019-04-05 株式会社三和化学研究所 Oral disnitegration tablet
CN104510717B (en) * 2013-09-27 2019-02-05 江苏豪森药业集团有限公司 Olanzapine orally-disintegrating tablet and preparation method thereof
CN108261399A (en) * 2016-12-30 2018-07-10 江苏豪森药业集团有限公司 Olanzapine oral disnitegration tablet and preparation method thereof
CN110151718A (en) * 2019-06-13 2019-08-23 厦门医学院 A kind of olanzapine orally disintegrating tablet and preparation method thereof
CN113730365A (en) * 2021-08-10 2021-12-03 杭州新诺华医药有限公司 Olanzapine orally disintegrating tablet and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
WO2003103629A1 (en) * 2002-06-10 2003-12-18 Laboratorios Vita, S. A. Orally disintegrating tablets and process for obtaining them.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
WO2003103629A1 (en) * 2002-06-10 2003-12-18 Laboratorios Vita, S. A. Orally disintegrating tablets and process for obtaining them.

Also Published As

Publication number Publication date
WO2006087629A2 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
WO2006124748A3 (en) Multicyclic compounds and methods of their use
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007127841A3 (en) Compositions and methods of preparation thereof
IL195488A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
MX2009000285A (en) Substituted piperidines that increase p53 activity and the uses thereof.
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
IL223477A (en) Pharmaceutical composition comprising modified uricase
PL1984357T3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
ZA200708361B (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
IL187976A0 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2007084857A3 (en) Methods and compositions for treating cell proliferative disorders
IL190915A0 (en) Dry formulations of aripiprazole
WO2005044200A3 (en) Methods and compositions for treating mcp-1 related pathologies
WO2006128143A3 (en) Hydantoin compounds
WO2007002823A3 (en) Formulations of conjugated estrogens and bazedoxifene
WO2007056625A3 (en) Thienopyridine b-raf kinase inhibitors
WO2006087629A3 (en) Rapidly disintegrating composition of olanzapine
GB0502787D0 (en) Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06710405

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6710405

Country of ref document: EP